La vendita allo scoperto per Quantum BioPharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Quantum BioPharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Quantum BioPharma (NASDAQ:QNTM) Azioni, Report sulle vendite allo scoperto

Quantum BioPharma

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma Ltd

News

PLTR

Palantir's Strategic Partnership With The Nuclear Company To Accelerate Nuclear Power Deployment With AI-Powered Operating System

TLRY

Tilray Medical Publishes Study Showing Higher Bioavailability Of Its Oral THC:CBD Extract Vs Nabiximols, Boosting Cannabis Therapy Insights

Needham analyst Scott Berg reiterates BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Buy and maintains $75 price target.

Price Target

Reiteration

Analyst Ratings

BILL

Needham Reiterates Buy on BILL Holdings, Maintains $75 Price Target

Bit Digital, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) ("Bit Digital" or the "Company"), today announced the pricing of an underwritten public offering of 75,000,000 ordinary shares at a public offering price of $2.00 per share. The aggregate gross proceeds to the Company from the offering, before deducting the underwriting discount and other offering expenses payable by the Company, will be $150.0 million. The Company intends to use the net proceeds from this offering to purchase Ethereum. In addition, the Company has granted the underwriters a&nbsp;30-day&nbsp;option to purchase an additional 11,250,000 ordinary shares. The offering is expected to close on or about June 27, 2025, subject to satisfaction of customary closing conditions.
 &nbsp;

Offerings

BTBT

Bit Digital Announces $150M Public Offering to Purchase Ethereum, Pricing Shares at $2.00 Each

ALDX

Aldeyra Therapeutics Receives FDA Special Protocol Assessment Agreement Letter For ADX-2191 To Treat Primary Vitreoretinal Lymphoma

<ul>
<li>Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity</li>
<li>Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study</li>
<li>No evidence of tachyphylaxis was observed in this study over the 6-week period</li>
<li>Management to Host Webcast and Conference Call Today at 8:00 A.M. ET</li>
</ul>
RESEARCH TRIANGLE PARK, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ISlXKW14w07rSGQv8qCPr8EIfXzfqS-fYOlTNY365ZYh2U5cuNT_0ukQd2GjclUd2ajeN_JZdjlKAq7oC8nwmIHZkPfL2NzV6AtxjCv2godaiS5EOmOzrqPMWSGNW--QxwgzL7S05WnK1pjseNABEMfIMfSdIxUN5W5-P37b6YoShoHuEqslSoc47Up-LYuinHNTYwqZqYJYJ7yzTYI593Qnhuqi_--ET9XZkvQLdhjkrniqFRmd_R7p04A0TnpdrucLIGEWkoJsOeUn1NTiC0yB5hp_6iECzAYKqzdUSrBJvZjVFvF_0iDUWXf0pZ3IEyDg6GGUlZKAGcAfK2obf9l3pzt-cb0QGP3_fU5ZqTo=">Opus Genetics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive topline results from VEGA-3, its second pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia. Presbyopia is an ophthalmic disorder that involves the progressive loss of ability to focus on close objects that results in blurred near vision, difficulty seeing in dim light, and eye strain.
The VEGA-3 trial met its primary endpoint, with a statistically significant 27.2% of participants treated with Phentolamine Ophthalmic Solution 0.75% achieving a ≥15-letter improvement in binocular distance-corrected near visual acuity (DCNVA), with less than a 5-letter loss in binocular best-corrected distance visual acuity (BCDVA) at 12 hours post-dose on Day 8, compared to 11.5% of patients on placebo (p&lt;0.0001). The trial also met key secondary efficacy endpoints, reinforcing the benefit observed.

VTRS

Viatris And Opus Genetics Say VEGA-3 Phase 3 Trial Meets Primary And Key Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity

MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision
Safety Profile Consistent With Previous Clinical Trials And No Treatment-Related Serious Adverse Events Reported In This Study
Targeting Application To U.S. FDA In Second Half of 2025
PITTSBURGH, June 26, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457548-1&amp;h=4247490512&amp;u=https%3A%2F%2Fwww.viatris.com%2Fen&amp;a=Viatris+Inc.">Viatris Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain, particularly in dim lighting conditions.
The VEGA-3 Phase 3 trial is a randomized, placebo-controlled, double-blind study, with a total of 545 patients who were randomized 3:2 to receive either MR-141 or placebo, once daily in the evening. In summary:
<ul>
<li>Significantly more patients treated in the MR-141 arm achieved the primary endpoint of Early Treatment Diabetic Retinopathy Study (ETDRS) (≥3-line) gain in binocular distance-corrected near visual acuity (DCNVA) and with less than 5 letters of loss in binocular best-corrected distance visual acuity (BCDVA) from baseline at 12 hours post-dose on Day 8, compared to placebo (p&lt;0.0001). &nbsp;</li>
<li>Significantly more patients treated in the MR-141 arm achieved ≥15-letters ETDRS (≥3-line) gain in DCNVA and with less than 5 letters of loss in BCDVA at 1-hour post-dose on Day 1 compared to those receiving placebo (p=0.0002). &nbsp;</li>
<li>Significant patient-reported functional benefit at Days 3, 8, and Week 6 were observed with patients reporting satisfaction with near vision upon awakening (p&lt;0.0001) and satisfaction with their improvement in near vision (p&lt;0.0001). &nbsp;</li>
<li>Patient reported significant improvement in near vision in dim/low light at Days 3, 8 and Week 6 compared with placebo (p&lt;0.0001). &nbsp;</li>
<li>No evidence of tachyphylaxis was observed during 6-week follow up. &nbsp;</li>
<li>MR-141 demonstrated a safety profile consistent with previous trials, with no new safety signal identified and no treatment-related serious adverse events reported in this study. The most common (≥5%) treatment-emergent adverse events included conjunctival hyperemia, instillation site irritation, and dysgeusia and were predominantly mild. Low rate of headache (2.6%) was reported over the study period. &nbsp;</li>
</ul>
VEGA-3 patients will continue to be monitored for long-term safety over 48 weeks. For more information on the VEGA-3 study design, refer to ClinicalTrials.gov (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457548-1&amp;h=2740410649&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06542497%3Fterm%3DNCT06542497%26rank%3D1___.YXAzOm9jdXBoaXJlOmE6bzoxNTQyMmNkZjViMTEzZTU3YzNhNjkwNzE1NWFjZGFjMzo2OjljYzU6MmI2NGRkMzdjNjA1YzA0MWQ0ODMwYTBlZTNjYTUzYzJhMzdlZWVmZjZlZTNlMzNjN2QyYmE3MzZmNWNlYzgxNjpwOlQ6Tg&amp;a=NCT06542497">NCT06542497</a>).
Opus Genetics and Viatris (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75%&nbsp;and grants exclusive rights to Viatris to commercialize phentolamine ophthalmic solution 0.75% in the U.S.

Viatris And Opus Genetics Report Top-Line Results From VEGA-3, Second Pivotal Phase 3 Trial Evaluating MR-141 In Treating Presbyopia; Targets Application To FDA In H2 2025

RMCO

Royalty Management Holding Corporatio Regained Full Compliance with Nasdaq Listing Standard

Reitar Logtech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RITR#NASDAQ">RITR</a>) ("Reitar" or the "Company"), a comprehensive logistics solutions provider and innovator in smart logistics technology, today announced that it has entered into a non-binding Memorandum of Understanding (the "MOU") with Rich Harvest Agricultural Produce Limited ("Rich Harvest"), a Hong Kong-based integrated agriculture enterprise. The MOU outlines the parties' intent to explore collaboration opportunities to integrate blockchain traceability, digital payment solutions, and smart cold chain technologies in cross-border agricultural supply chains.
&nbsp;
Collaboration Overview
&nbsp;
The parties intend to explore the development of an integrated technology platform that would combine blockchain-based traceability systems with automated cold chain infrastructure. Rich Harvest operates multiple farming bases across mainland China covering approximately 1,333 hectares (20,000 mu), with established farm-to-table traceability systems using barcode and RFID tracking. Under the proposed collaboration, Rich Harvest would leverage Reitar's expertise in automated cold chain infrastructure and technology solutions.
&nbsp;
The Company's contributions to the potential collaboration would include:
&nbsp;
●&nbsp;&nbsp;&nbsp;&nbsp;IoT sensing technology for real-time monitoring &nbsp;
●&nbsp;&nbsp;&nbsp;&nbsp;Access to large automated cold storage facilities in Hong Kong &nbsp;
●&nbsp;&nbsp;&nbsp;&nbsp;Token-based financing models for supply chain operations &nbsp;
Strategic Framework
&nbsp;
The MOU outlines the parties' intent to explore three potential collaboration areas:
&nbsp;
Blockchain Traceability System Development: Co-development of a ledger system for recording farming, harvesting, and transportation data to enhance end-to-end visibility in the supply chain.
&nbsp;
Digital Payment Integration: Subject to applicable regulatory approvals and requirements, explore the implementation of digital payment solutions that could include the Company's proposed stablecoin payment system to potentially automate settlements and related processes.
&nbsp;
Smart Cold Chain Integration: Integration of Rich Harvest's agricultural operations with Reitar's automated cold storage capabilities and logistics solutions, exploring AI-driven temperature control and inventory management systems.
&nbsp;
Implementation Timeline
&nbsp;
The MOU contemplates a phased approach to potential collaboration:
&nbsp;
Phase 1 (targeted for Q4 2025): Potential pilot program involving approximately 30 tons per day of vegetable exports from Rich Harvest's Guizhou farming base to Hong Kong, with deployment of IoT sensors at harvest and packaging stations and integration with Reitar's large Kwai Chung cold storage facility as a central distribution hub.
&nbsp;
Phase 2 (targeted for Q1 2026): Potential onboarding of Hong Kong supermarkets and wet markets for digital payment settlement systems.
&nbsp;
 &nbsp;
&nbsp;
&nbsp;
Terms of the MOU
&nbsp;
The MOU is non-binding and represents the parties' intent to explore potential collaboration opportunities. The parties intend to execute definitive agreements within 120 days following the signing of the MOU. The MOU has an initial term of 24 months and may be terminated by either party with 90 days' written notice. Any definitive collaboration would be subject to the execution of binding agreements and applicable regulatory approvals.

RITR

Reitar Logtech Holdings Announced MOU With Rich Harvest Agricultural Produce To Develop "Blockchain + Stablecoin + Smart Cold Chain" Smart Agricultural Ecosystem

Full exit of Individual Retirement variable annuities
Significant value upside for shareholders with $2.8 billion transaction value
Acceleration of Corebridge's capital return strategy with $2.1 billion in net distributable proceeds, substantial majority of which will be returned via share repurchases
Reaffirming attractive financial targets while reducing risk
Board of Directors authorizes $2 billion increase to share repurchase program
Corebridge Financial, Inc. ("Corebridge" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) today announced that it has entered into an agreement with CS Life Re, a subsidiary of Venerable Holdings, Inc. ("Venerable") to reinsure all the variable annuities of its Individual Retirement business, with account value totaling $51 billion as of March 31, 2025. The transaction is valued at $2.8 billion, consisting of both ceding commission and capital release, and will generate approximately $2.1 billion of net distributable proceeds after-tax for Corebridge.
Transaction Overview
<ul>
<li>Corebridge will reinsure its entire Individual Retirement variable annuity in-force book, amounting to $51 billion of total account value as of March 31, 2025, through reinsurance transactions with the Company's insurance subsidiaries American General Life Insurance Company ("AGL") and The United States Life Insurance Company in the City of New York ("USL") &nbsp;</li>
<li>The $51 billion of total account value ("AV") includes $5 billion of General Account AV (reinsured 100% on a coinsurance basis) and $46 billion of Separate Account AV (reinsured on a modified coinsurance basis) &nbsp;</li>
<li>New variable annuity contracts written through the Individual Retirement business and issued by AGL will be reinsured through an ongoing flow reinsurance agreement that will begin once the transaction is closed &nbsp;</li>
<li>The transaction includes the sale of a related investment adviser and manager for portfolios offered in Corebridge variable annuity products (SAAMCo) &nbsp;</li>
<li>The transaction also includes extensive counterparty protections, including comfort trusts with defined investment guidelines, over-collateralization requirements, and a protective hedging arrangement &nbsp;</li>
<li>The AGL transaction is expected to close in the third quarter while the USL transaction and the sale of SAAMCo are expected to close in the fourth quarter, subject to customary closing conditions including regulatory approvals</li>
</ul>
Financial Overview
<ul>
<li>Attractive earnings multiple of approximately 9–10x 2026E and 2027E operating earnings &nbsp;</li>
<li>Exits a portfolio with historically volatile GAAP earnings and tail risk exposure &nbsp;</li>
<li>AATOI expected to decrease by approximately $300 million in 2026 and the impact is expected to decrease materially over the next few years &nbsp;</li>
<li>Increases the Life Fleet RBC ratio by over 50 points before any share repurchases</li>
</ul>

CRBG

Corebridge Agrees With CS Life Re To Reinsure All Variable Annuities Of Individual Retirement Business, With Account Value Totaling $51B As Of March 31, 2025

<ul>
<li>Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to on-demand treatment in patients 12 years and older</li>
<li>HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection that required minimal preparation</li>
</ul>

Biotech

Large Cap

Health Care

General

Pfizer Announced Topline Results From The Phase 3 Basis Study Of Hympavzi (Marstacimab) For Adults And Adolescents With Hemophilia A Or B With Inhibitors, The Study Met The Primary Endpoint And Key Secondary Bleeding Endpoints Demonstrating Superiority Of Once-Weekly Subcutaneous Hympavzi In Improving Key Bleeding Outcomes Compared To On-demand Treatment

Lindsay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNN#NYSE">LNN</a>) reported quarterly earnings of $1.78 per share which beat the analyst consensus estimate of $1.41 by 26.69 percent. This is a 3.78 percent decrease over earnings of $1.85 per share from the same period last year. The company reported quarterly sales of $169.464 million which beat the analyst consensus estimate of $157.867 million by 7.35 percent. This is a 21.74 percent increase over sales of $139.199 million the same period last year.

Earnings

Earnings Beats

Lindsay Q3 EPS $1.78 Beats $1.41 Estimate, Sales $169.464M Beat $157.867M Estimate

Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $320 to $377.

ALNY

Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $377

Mccormick Says It Is "Well Positioned" To Mitigate Current Tariff Related Costs, Fuel Growth Investments, And Expand Operating Margins

2025 Guidance Summary
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Unit abbreviations: oz = troy ounce, $/oz sold = U.S. dollars per gold ounce sold, $m = million of U.S. dollars</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3" rowspan="1">2025 Guidance Summary</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Florida Canyon Mine: gold production</td>
<td colspan="1" rowspan="1">ounces</td>
<td colspan="1" rowspan="1">70,000 - 75,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Florida Canyon Mine: total cash cost1</td>
<td colspan="1" rowspan="1">$/oz sold</td>
<td colspan="1" rowspan="1">$1,800 - $1,900</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Florida Canyon Mine: mine-site all-in sustaining cost ("AISC")1</td>
<td colspan="1" rowspan="1">$/oz sold</td>
<td colspan="1" rowspan="1">$2,450 - $2,550</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Florida Canyon Mine: sustaining capital expenditures and leases</td>
<td colspan="1" rowspan="1">$m</td>
<td colspan="1" rowspan="1">$48.0 - $53.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Florida Canyon Mine: growth capital expenditures</td>
<td colspan="1" rowspan="1">$m</td>
<td colspan="1" rowspan="1">$8.0 - $10.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">DeLamar &amp; Nevada North Projects: project advancement</td>
<td colspan="1" rowspan="1">$m</td>
<td colspan="1" rowspan="1">$14.5 - $15.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate: general and administrative expenses2</td>
<td colspan="1" rowspan="1">$m</td>
<td colspan="1" rowspan="1">$7.5 - $8.0</td>
</tr>
</tbody>
</table>
</figure>

Guidance

ITRG

Integra Sets 2025 Guidance: Florida Canyon To Produce 70,000-75,000 Ounces Of Gold, Total Cash Costs Between $1,800-$1,900 per Ounce

McCormick &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) affirms FY2025 Adj EPS guidance from $3.03-$3.08 to $3.03-$3.08 vs $3.04 analyst estimate..

McCormick & Co Affirms FY2025 Adj EPS Guidance of $3.03-$3.08 vs $3.04 Est; Projects Net Sales Growth Of 0%-2%

71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile
83% ORR (10/12) in patients across doses selected for ongoing dose expansion study
Responses observed in patients with low PD-L1 and/or CLDN18.2 expression
Updated results to be presented at ESMO GI on July 2nd
Company to host investor event on July 8th
ROCKVILLE, Md., June 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of ESMO Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) abstract #388MO related to positive data from a Phase 1b study evaluating givastomig in combination with nivolumab and mFOLFOX6 chemotherapy for metastatic gastric cancers. An objective response rate (ORR) of 71% (12/17) was observed across all dose levels with an ORR of 83% (10/12) observed at dose levels selected for the ongoing dose expansion study (8 and 12 mg/kg). Responses were rapid and deepened over time, and were observed in tumors with low levels of PD-L1 expression and/or low levels of Claudin 18.2 (CLDN18.2) expression. There was a favorable safety profile, with low incidence of GI and liver toxicities. I-Mab intends to host a virtual investor event on Tuesday, July 8th (register <a href="https://www.globenewswire.com/Tracker?data=c9ofWXSpX61CpagEDM0pY2xFqsAvs5oQ7KJu5iG213tkH0uBybl7M-C1uCD8XzyScGl8cEy5ilx4F8DcGyxIugguApQveQvVCOSTJXtnFDA=">here</a>) to recap the data being presented at ESMO GI.
The abstract is based on the results of the dose escalation part of a Phase 1b study (NCT04900818) evaluating the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of givastomig used in combination with nivolumab and mFOLFOX6 as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ intensity in ≥1% of cells). The primary endpoint is safety. The study only enrolled patients in the U.S.

IMAB

I-Mab Publishes Abstract Related To Data From Phase 1b Study Evaluating Givastomig In Combination With Nivolumab And mFOLFOX6 Chemotherapy For Metastatic Gastric Cancers In ESMO GI 2025

NATO's 32 member states agreed to increase defense spending to 5% of GDP by 2035, representing a significant increase from the long-standing 2% benchmark.
The new target is the most ambitious in the alliance's 76-year-old history and a major political win for <a target="_blank" href="https://www.benzinga.com/topic/donald-trump" rel="noreferrer noopener">U.S. President</a> Donald Trump, who had long criticized European allies for underfunding their militaries.
"Our investments will ensure we have the forces, capabilities, resources, infrastructure, warfighting readiness, and resilience needed to deter and defend in line with our three core tasks of deterrence and defence, crisis prevention and management, and cooperative security," the <a target="_blank" href="https://www.nato.int/cps/en/natohq/official_texts_236705.htm" rel="noreferrer noopener">press release</a> stated.
The agreement includes a 3.5% floor for core defense spending, encompassing troops, weapons, and ammunition, and allows up to 1.5% for related areas, such as infrastructure, cybersecurity, and civilian preparedness.
Members must follow credible annual progress plans, with a major review anticipated for 2029. The declaration also commits allies to expand defense industrial cooperation, eliminate trade barriers, and invest in emerging technologies such as drones and satellite systems.
In a message that Trump shared on social media and AP News <a target="_blank" href="https://apnews.com/article/trump-rutte-text-message-nato-signal-6263810ac3ca77a5bf7366499f51c772" rel="noreferrer noopener">relayed</a>, NATO Secretary General Mark Rutte said that Trump "will achieve something no American president in decades could get done."
Still, major issues were sidestepped. The summit delivered no new aid for Ukraine, offered no updated posture on Russia, and avoided discussing China. "All the big challenges were left off the agenda," Torrey Taussig, a former Europe director at the U.S. National Security Council, said, according <a target="_blank" href="https://www.nytimes.com/2025/06/25/world/europe/nato-increase-military-spending-trump.html" rel="noreferrer noopener">to</a> the New York Times.
<h2 class="wp-block-heading">Carney Leans on Critical Minerals</h2>
The 5% goal significantly widens what counts as defense spending, offering nations flexibility to invest in long-term resilience—such as transportation networks and innovation hubs—tied to national security. NATO leaders framed the move as essential to confronting growing threats and maintaining credible deterrence.
"We are investing at the scale and urgency required by the new era of strategic competition," the official summit document stated.
Canada's Prime Minister Mark Carney noted that the country is ready to meet the new spending requirement, estimating that a 5% pledge would cost about CA$150 billion ($109 billion) over the next decade. Still, he pointed out that roughly one-third of that is already underway, with investments in critical mineral infrastructure that support defense resilience.
Carney clarified his country's focus on advanced technologies, such as drones, AI, satellites, and cyber warfare—not heavy platforms like carriers—and said spending would evolve as threats change. "We'll do a review in four or five years," he said <a target="_blank" href="https://financialpost.com/news/economy/carney-says-canada-can-hit-new-110-billion-nato-bill-with-mines" rel="noreferrer noopener">per</a> Financial Post, adding that defense and trade talks with Trump remain active.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46109160/japans-top-trade-negotiator-calls-trumps-25-auto-tariffs-unacceptable-amid-ongoing-talks" target="_blank" rel="noreferrer noopener">Japan's Top Trade Negotiator Calls Trump's 25% Auto Tariffs' Unacceptable' Amid Ongoing Talks</a></li>
</ul>
Image via Shutterstock

Government

Eurozone

Financing

Politics

Global

Markets

Market Vectors Environmental Services Index Fund

iShares Dow Jones US Aerospace & Defense Index Fund

ROKT

NATO's New 5% Target For Defense A Win for Trump; Carney Turns To Critical Minerals

NATR

Nature's Sunshine Announces Pricing Of Secondary Offering Of Common Stock, Selling 2,854,607 Shares At $12 Each

General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) has issued a recall for over 62,468 vehicles in the U.S. over a brake pressure sensor issue.
What Happened: The Detroit-based automaker recalled Chevrolet Silverado Pickup trucks manufactured from 2019 to 2024, Reuters reported on Thursday.
The issue with the brake pressure sensor, which could cause a fluid leak leading to increased chances of an electrical short and a fire, stems from the use of an unauthorized chemical during the assembly of the brake line by the company's supplier, the report said.&nbsp;
The report also suggests that over 1% of the recalled Chevrolet Silverado vehicles are affected by the issue, adding that an underhood fire could occur when the vehicle is switched off.
Why It Matters: The recall comes as GM's fellow Detroit-based automaker, Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), recently <a href="https://www.benzinga.com/markets/tech/25/06/46068633/ford-recalls-aviator-suvs-as-adhesive-issue-adds-to-automakers-mounting-recall-woes">issued multiple recalls</a> for several vehicles in its lineup.  
GM, along with other auto manufacturers in the U.S., issued a statement <a href="https://www.benzinga.com/markets/tech/25/06/46108517/gm-toyota-call-out-nhtsa-over-safety-rules-say-regulator-is-stifling-innovation-holding-back-autonomous-vehicle-future">criticizing the NHTSA</a>, or National Highway Traffic Safety Administration, for "stifling innovation."
GM also recently <a href="https://www.benzinga.com/markets/tech/25/06/45899175/general-motors-cfo-says-4-billion-investment-will-allow-company-to-rebalance-production-amid-trump-tariffs">invested over $4 billion</a> in its domestic production facilities, which the automaker says could help the company rebalance production as U.S. President Donald Trump's auto tariffs cause uncertainty in the auto industry.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="213" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26062128/GM-26-JUN-2025-1024x213.jpg" alt="" class="wp-image-963018" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26062128/GM-26-JUN-2025-1024x213.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26062128/GM-26-JUN-2025-300x62.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26062128/GM-26-JUN-2025-768x160.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26062128/GM-26-JUN-2025-1536x319.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26062128/GM-26-JUN-2025.jpg 1553w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
GM scores well on Value and Quality metrics, while also offering satisfactory Momentum and Growth. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46109160/japans-top-trade-negotiator-calls-trumps-25-auto-tariffs-unacceptable-amid-ongoing-talks">Japan&#8217;s Top Trade Negotiator Calls Trump&#8217;s 25% Auto Tariffs &#8216;Unacceptable&#8217; Amid Ongoing Talks</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

Tech

General Motors Recalls Over 62,000 Vehicles For Brake Issue That Could Potentially Result In A Fire: Report

Press Releases

Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis

Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.

Comments

Quantum BioPharma

Vendite allo scoperto

Quantum BioPharma (NASDAQ:QNTM) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO